In his role as vice president of preclinical development, Mr Tabrizi will guide the company’s therapeutic antibody discovery programs into clinical development. He will also lead compound assessment, pharmacology, toxicology, bioanalytics and clinical immunology efforts, and will provide strategic input for target selection and generation of new drug concepts.
Mr Tabrizi joins AnaptysBio from MedImmune, a subsidiary of AstraZeneca. At MedImmune he served as director of translational sciences and designed and implemented strategies for the development of therapeutic monoclonal antibodies from discovery to the clinic. He also has held various leadership and scientific positions at AstraZeneca, Abgenix (now Amgen), Coulter Pharmaceutical (now Corixa), and TAP Holdings.
Tom Smart, chairman and CEO of AnaptysBio, said: “Mohammad will manage preclinical development of our internal therapeutic antibody product candidates. This is a key hire for AnaptysBio as we move to the next stages of advancing product candidates arising from our somatic hypermutation platform.”